Zimbabwe has turned down a substantial US healthcare agreement worth $367m (£272m) over five years due to Washington's demand for confidential biological samples.
This move became public after a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative has since clarified that the United States was requesting health data for research and commercial gain while was unwilling to share the benefits from future treatments.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more negotiations to find a deal suitable to both sides so the country's critical HIV programme can be sustained.
Wider Implications
This development comes after a similar case in Kenya, where a high court halted a similar health funding agreement following legal challenges were raised about the security of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government agreements to enhance transparency and responsibility.
Based on reports, Sixteen African countries have so far agreed to similar health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, with no corresponding promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"Effectively, our nation would supply the basic resources for medical research with no certainty that the end products would be accessible to our citizens should a future health crisis emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of bilateral deals were disrupting systems already established through the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This mechanism is designed to ensure that when a nation provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
These objections over the US deal "must not be interpreted as opposition to America," he added.
"We encourage ongoing discussions with our American counterparts on how future collaboration might be arranged in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body stated it acknowledged the government's concerns, but recommended that negotiations should continue considering much of the nation's Aids initiatives depended on foreign aid.
"In cases where technical issues exist, such as those relating to data governance or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," it said.
The halted deal underscores the complex debate between receiving vital foreign assistance and safeguarding a country's data in an increasingly interconnected world.